Orexigen Therapeutics is a public American pharmaceutical company focused on development of treatments for obesity. The company is based in La Jolla, California and was established by Eckard Weber in 2002. As a public company, Orexigen is traded on the NASDAQ exchange under the stock symbol OREX. The company has a single product, Contrave, approved for use in the United States in 2014. The launch of Contrave was conducted through a sales force of 900. Observation of the market performance of Qsymia and Belviq suggest overall low demand for pharmaceutical obesity therapies, calling into question earnings potential for Orexigen's offering.